Stock BPMC BLUEPRINT MEDICINES CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

News Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
102.8 USD +0.41% Intraday chart for Blueprint Medicines Corporation -2.05% +11.46%
May. 23 Blueprint Medicines Says BLU-222 Combination Well Tolerated for Inhibitor in Type of Breast Cancer MT
May. 23 Blueprint Medicines Corporation to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Blueprint Medicines Says BLU-222 Combination Well Tolerated for Inhibitor in Type of Breast Cancer
MT
Blueprint Medicines Corporation to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting
CI
Stephens Starts Blueprint Medicines With Overweight Rating, $140 Price Target
MT
Blueprint Medicines Insider Sold Shares Worth $1,050,000, According to a Recent SEC Filing
MT
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Goldman Sachs Adjusts Price Target on Blueprint Medicines to $168 From $121, Maintains Buy Rating
MT
Leerink Upgrades Blueprint Medicines to Market Perform, Price Target at $97
MT
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT/AYVAKYT Full Year Revenue Guidance
AQ
Wedbush Raises Blueprint Medicines' Price Target to $120 From $110 After Stronger-Than-Expected Q1 Results, Keeps Outperform Rating
MT
Blueprint Medicines Shares Rise After Q1 Swings to Net Income, Revenue Rises
MT
Transcript : Blueprint Medicines Corporation, Q1 2024 Earnings Call, May 02, 2024
Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Posts Q1 Revenue $96.1M, vs. Street Est of $81.4M
MT
Blueprint Medicines: Q1 Earnings Snapshot
AQ
Blueprint Medicines Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Blueprint Medicines Corporation Revises Revenue Guidance for the Full Year 2024
CI
Transcript : Blueprint Medicines Corporation - Special Call
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
PR
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
PR
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Blueprint Medicines Insider Sold Shares Worth $2,188,265, According to a Recent SEC Filing
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BPMC Stock
  4. News Blueprint Medicines Corporation